Do cytokines play role in the pathogenesis of mucopolysaccharidosis

OKUR, ILYAS; Inci, Aslı; YILMAZ, CANAN; Tumer, Leyla; Ezgu, Fatih Suheyl; Biberoglu, Gursel

doi:10.5455/medscience.2021.09.312

Do cytokines play role in the pathogenesis of mucopolysaccharidosis

Aslı İNCİ, (Gazi University School of Medicine, Division of Pediatric Metabolism and Nutrition, Ankara, Turkey)

Canan YILMAZ, (Gazi University School of Medicine, Division of Pediatric Metabolism and Nutrition, Ankara, Turkey)

İlyas OKUR, (Gazi University School of Medicine, Division of Pediatric Metabolism and Nutrition, Ankara, Turkey)

Gursel Biberoglu, (Gazi University School of Medicine, Division of Pediatric Metabolism and Nutrition, Ankara, Turkey)

Fatih Süheyl EZGÜ, (Gazi University School of Medicine, Division of Pediatric Metabolism and Nutrition, Ankara, Turkey)

Leyla TÜMER (Gazi University School of Medicine, Division of Pediatric Metabolism and Nutrition, Ankara, Turkey)

Medicine Science

1 0

Yıl: 2021 Cilt: 10 Sayı: 4 Sayfa Aralığı: 1492 - 1497 Metin Dili: İngilizce DOI: 10.5455/medscience.2021.09.312 İndeks Tarihi: 16-05-2022

Do cytokines play role in the pathogenesis of mucopolysaccharidosis

Öz:

The mucopolysaccharidoses (MPS) are a heterogeneous group of inborn errors of metabolism with an increased deposition of glycosaminoglycans in lysosomes (GAGs). In MPS, GAG leads to inflammatory pathway activation. In MPS models, studies have shown that accumulation of glycosaminoglycans in lysosomes causes activation of oxidative stress, and then apoptosis is triggered. In this study, the aim was to show whether GAG deposition could trigger the inflammatory processes via cytokines. Forty-three MPS patients as patient group and 29 healthy children as control group were included in the study. Samples were taken before and after ERT from 8 MPS patients. 15 patients were treated with enzyme replacement and 28 patients could not be treated with the enzyme. Tumor necrosis alpha (TNF-α), interleukin 1-beta (IL-1β), interleukin 6 (IL-6) levels were studied by ELISA method. When cytokine levels of MPS patients and control groups were compared, cytokines were found to significantly increased (p≤0.05) in MPS patients. Pretreatment IL-6 and posttreatment IL-6 and IL-1β levels of patients treated with enzyme replacement therapy (ERT) were found near to control group. Pre-treatment and post-treatment TNF-α levels were found significantly higher in MPS patients than the control group that was significantly higher in the post-treatment group. In the MPS group of ERT treatment, IL-1β and TNF-α levels decreased significantly after ERT(p≤0.05). MPS patients had higher levels of IL-6 and TNF-α levels than the control group that revealed inflammatory pathway activation in MPS patients. The inflammatory process is prominent in MPS patients that GAG deposition leads to increase pro-inflammatory cytokines and oxidative stress. Although enzyme replacement therapy reduces glycosaminoglycan accumulation by preventing cytokine production, it might be more effective when given with antiinfllammatory mediators.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child,1995;72:263–7.
2. Muenzer J, Wraith JE, L Clarke A. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009;123:19–29.
3. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 2004;144:27–34.
4. Ohmi K, Greenberg DS, Rajavel KS, et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003;100:1902–7.
5. Bernsen PL, Wevers RA, Gabreels FJ, et al. Phenotypic expression in mucopolysaccharidosis VII. J Neurol Neurosurg Psychiatry 1987;50:699– 703.
6. Cleary MA, Wraith JE. Management of mucopolysaccharidosis type III. Arch Dis Child 1993; 69:403–6.
7. Langford-Smith A, Langford-Smith KJ, Jones SA, et al. Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test. PLoS One 201;6:25717
8. Langford-Smith A, Malinowska M, Langford-Smith KJ, et al.Hyperactive behaviour in the mouse model of mucopolysaccharidosis IIIB in the open field and home cage environments. Genes Brain Behav, 2011;10:673–82
9. Vitner EB, Platt EM,Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010;285:20423–7.
10. Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: A possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001;81:1319–28.
11. Simonaro CM, D’Angelo M, Haskins ME, et al. Joint and bone disease in mucopolysaccharidoses VI and VII: Identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005; 57:701–7.
12. Simonaro CM, D'Angelo M, He X, et al. Mechanism of glycosaminoglycanmediated bone and joint disease: Implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008;172:112–22.
13. Hoshino K. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol,1999;162:3749–52 . 14. Taylor KR, Yamasaki K , Radek KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007;282:18265–75.
15. Xia Y, Yamagata K, Krukoff TL. Differential expression of the CD14/ TLR4 complex and inflammatory signaling molecules following i.c.v. administration of LPS. Brain Res 2006;1095:85–95.
16. Scherz-Shouval R, Shvets E, Fass E, et al. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007;26:1749–60.
17. Vogler C , Levy B, Galvin NJ, et al. Enzyme replacement in murine mucopolysaccharidosis type VII: Neuronal and glial response to β-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res. 1999;45:838–44.
18. Sly WS. Enzyme replacement therapy for lysosomal storage disorders: Successful transition from concept to clinical practice. Mol Med. 2004;101:100–04.
19. Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: Progress with enzyme replacement therapy. Drugs. 2007;67:2697–716.
20. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun. 2007;388:621-5.
21. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010; 14:2592-603
22. Fang H, Chen J, Lin S, et al. CD36-mediated hematoma absorption following intracerebral hemorrhage: negative regulation by TLR4 signaling. J Immunol. 2014;192:5984–92.
23. Jacobsen JH, Watkins LR, Hutchinson MR. Discovery of a novel site of opioid action at the innate immune pattern-recognition receptor TLR4 and its role in addiction. Int Rev Neurobiol. 2014;118:129–63.
24. Wang C, Sun H, Song Y,Ma Z, Zhang G, Gu X, et al. Pterostilbene attenuates inflammation in rat heart subjected to ischemia-reperfusion: role of TLR4/ NF-kappa B signaling pathway. Int J Clin Exp Med. 2015;8:1737–46.
25. Xing ME, Susan W, Ponder KP. The effect of Tlr4 and/or C3 Deficiency and of Neonatal Gene Therapy on Skeletal Disease in Mucopolysaccharidosis VII mice Mol Genet Metab. 2015;114:209–16.
26. Arfi A, Richard M, Gandolphe C, et al. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of longterm aspirin treatment, Mol. Genet. Metab. 2011;103:18–25.
27. Metcalf AJ, Linders B, Wu S, et al. Up regulation of elastase activity in aorta in mucopolysaccaridosis I and VII may be due to increased cytokine expression. Mol Genet Metab. 2010;99:396-407.
28. Ausseil J, Desmaris N, Bigou S, et al. Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One. 3,2008;2296.
29. Villani GRD, Gargiulo N, Faraonio R. Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J. Neurosci. Res. 2007;85:612–22
30. Calogera M, Simonaroa YG, Eliyahu E, et al. Involvement of the Tolllike receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidoses. PNAS. 2010;107:222-7
31. Nakae S, Asano M, Horai R, et al. Interleukin-1β, but not interleukin- 1α, is required for Tcell- dependent antibody production. Immunology. 2001;104:402–9.
32. Cairns CB, Panacek EA, Harken AH, et al. Bench to Bedside Tumor Necrosis Factor-alpha:From Inflammation to Resuscitation. Acad Emerg Med. 2000;7:930–41.
33. Elenkov IJ, Chrousos GP. Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity. Ann N Y Acad Sci. 2002; 966:290–303.
34. Vgontzas AN, Bixler EO, Lin HM, et al. IL-6 and Its Circadian Secretion in Humans. Neuroimmunomodulation. 2005;12:131–40.
35. Polgreen EL, Vehe KR, Rudser K, et al. Elevated TNF-α is associated with pain and physical disability in mucopolysaccaridosis types I,II and VI. Mol Genet Metab. 2016;117:427-30
36. Abhijit RP, Simon AJ, Iain AB, et al.Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy. PloS One 2018 https://doi.org/10.1371/journal.pone.0203216
37. Bruna D, Desirèe PM, Giovana BB, et al . Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophysica Acta. 2015;1852:1012–19
38. Shinhar SY, Zablocki H, Madgy DN. Airway management in mucopolysaccharide storage disorders. Arch Otolaryngol Head Neck Surg. 2004:130; 233–37.

APA	Inci A, YILMAZ C, OKUR I, Biberoglu G, Ezgu F, Tumer L (2021). Do cytokines play role in the pathogenesis of mucopolysaccharidosis. , 1492 - 1497. 10.5455/medscience.2021.09.312
Chicago	Inci Aslı,YILMAZ CANAN,OKUR ILYAS,Biberoglu Gursel,Ezgu Fatih Suheyl,Tumer Leyla Do cytokines play role in the pathogenesis of mucopolysaccharidosis. (2021): 1492 - 1497. 10.5455/medscience.2021.09.312
MLA	Inci Aslı,YILMAZ CANAN,OKUR ILYAS,Biberoglu Gursel,Ezgu Fatih Suheyl,Tumer Leyla Do cytokines play role in the pathogenesis of mucopolysaccharidosis. , 2021, ss.1492 - 1497. 10.5455/medscience.2021.09.312
AMA	Inci A,YILMAZ C,OKUR I,Biberoglu G,Ezgu F,Tumer L Do cytokines play role in the pathogenesis of mucopolysaccharidosis. . 2021; 1492 - 1497. 10.5455/medscience.2021.09.312
Vancouver	Inci A,YILMAZ C,OKUR I,Biberoglu G,Ezgu F,Tumer L Do cytokines play role in the pathogenesis of mucopolysaccharidosis. . 2021; 1492 - 1497. 10.5455/medscience.2021.09.312
IEEE	Inci A,YILMAZ C,OKUR I,Biberoglu G,Ezgu F,Tumer L "Do cytokines play role in the pathogenesis of mucopolysaccharidosis." , ss.1492 - 1497, 2021. 10.5455/medscience.2021.09.312
ISNAD	Inci, Aslı vd. "Do cytokines play role in the pathogenesis of mucopolysaccharidosis". (2021), 1492-1497. https://doi.org/10.5455/medscience.2021.09.312

APA	Inci A, YILMAZ C, OKUR I, Biberoglu G, Ezgu F, Tumer L (2021). Do cytokines play role in the pathogenesis of mucopolysaccharidosis. Medicine Science, 10(4), 1492 - 1497. 10.5455/medscience.2021.09.312
Chicago	Inci Aslı,YILMAZ CANAN,OKUR ILYAS,Biberoglu Gursel,Ezgu Fatih Suheyl,Tumer Leyla Do cytokines play role in the pathogenesis of mucopolysaccharidosis. Medicine Science 10, no.4 (2021): 1492 - 1497. 10.5455/medscience.2021.09.312
MLA	Inci Aslı,YILMAZ CANAN,OKUR ILYAS,Biberoglu Gursel,Ezgu Fatih Suheyl,Tumer Leyla Do cytokines play role in the pathogenesis of mucopolysaccharidosis. Medicine Science, vol.10, no.4, 2021, ss.1492 - 1497. 10.5455/medscience.2021.09.312
AMA	Inci A,YILMAZ C,OKUR I,Biberoglu G,Ezgu F,Tumer L Do cytokines play role in the pathogenesis of mucopolysaccharidosis. Medicine Science. 2021; 10(4): 1492 - 1497. 10.5455/medscience.2021.09.312
Vancouver	Inci A,YILMAZ C,OKUR I,Biberoglu G,Ezgu F,Tumer L Do cytokines play role in the pathogenesis of mucopolysaccharidosis. Medicine Science. 2021; 10(4): 1492 - 1497. 10.5455/medscience.2021.09.312
IEEE	Inci A,YILMAZ C,OKUR I,Biberoglu G,Ezgu F,Tumer L "Do cytokines play role in the pathogenesis of mucopolysaccharidosis." Medicine Science, 10, ss.1492 - 1497, 2021. 10.5455/medscience.2021.09.312
ISNAD	Inci, Aslı vd. "Do cytokines play role in the pathogenesis of mucopolysaccharidosis". Medicine Science 10/4 (2021), 1492-1497. https://doi.org/10.5455/medscience.2021.09.312